Introduction: Addressing Oligonucleotide Therapeutic Scale-Up, Purity Requirements, and Regulatory Compliance Pain Points
For biopharmaceutical R&D directors, CMC managers, and gene therapy developers, manufacturing oligonucleotides (ASOs, siRNA, aptamers, CpG, guide RNA) under Good Manufacturing Practice (GMP) standards is a critical bottleneck for clinical development and commercialization. Oligonucleotide therapeutics—such as antisense oligonucleotides (ASOs: Spinraza, Exondys 51, Vyondys 53, Viltepso), small interfering RNA (siRNA: Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio), and aptamers (Macugen)—require high purity (>90–98%), precise sequence fidelity, controlled impurity profiles (truncated sequences, deletion sequences, phosphorothioate stereochemistry), and extensive analytical characterization (mass spectrometry, HPLC, CE, endotoxin, sterility). Research-grade synthesis (1–50 µmol scale, <90% purity) is insufficient for clinical trials or commercial launch. GMP oligonucleotide production addresses these gaps with large-scale synthesizers (1–100+ mmol), validated purification methods (PAGE, HPLC, IEX, RP), rigorous quality control, and regulatory documentation (FDA IND/IMPD, BLA, MAA). As oligonucleotide approvals accelerate (10+ approved therapeutics, 500+ clinical trials), and new modalities (circRNA, CRISPR guide RNA, mRNA) demand GMP-grade oligos, demand for CDMO outsourcing is surging. Global Leading Market Research Publisher QYResearch announces the release of its latest report “GMP Oligonucleotide Production – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global GMP Oligonucleotide Production market, including market size, share, demand, industry development status, and forecasts for the next few years.
For outsourcing managers, CMC directors, and biotech investors, the core pain points include achieving high purity (>95%) and yield (>50%), controlling impurity profiles (N-1, N-2, deletion, phosphorothioate diastereomers), and reducing manufacturing cost ($50k–500k per batch) for clinical and commercial supply. According to QYResearch, the global GMP oligonucleotide production market was valued at US$ 375 million in 2025 and is projected to reach US$ 642 million by 2032, growing at a CAGR of 8.1% .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097906/gmp-oligonucleotide-production
Market Definition and Core Capabilities
GMP oligonucleotide production refers to synthesis, purification, analytical testing, and formulation of oligonucleotides under strict Good Manufacturing Practice (GMP) standards. Core capabilities:
- Solid-Phase Synthesis (Phosphoramidite Method): Automated synthesizers (1–100+ mmol scale, 1–200 columns). 3′ to 5′ synthesis cycle: detritylation, coupling (phosphoramidite + activator), capping, oxidation (I₂) or sulfurization (for phosphorothioate backbone). DNA, RNA, 2′-O-methyl, 2′-fluoro, 2′-MOE, LNA, PNA, phosphorothioate (PS) modifications.
- Purification: PAGE (polyacrylamide gel electrophoresis) – research scale, low throughput. HPLC – IEX (ion exchange), RP (reverse phase), SEC (size exclusion) for GMP. Oligonucleotide purity >90–98%, removal of truncated sequences (N-1, N-2), deletion sequences, failure sequences. Process impurity control (depurination, depyrimidination, oxidation).
- Analytical Testing: Mass spectrometry (ESI-MS, MALDI-TOF) for molecular weight confirmation and sequence fidelity. HPLC (IEX, RP) for purity, impurity profiling. Capillary electrophoresis (CE) for size-based purity. Endotoxin, bioburden, sterility (for parenteral products). Residual solvents (acetonitrile, pyridine, dichloromethane). Identity, strength, quality, purity.
- Formulation: Lyophilization (freeze-drying) for stability, liquid formulation (buffered saline, phosphate buffer, citrate buffer). Fill-finish (vials, syringes) under aseptic conditions.
- Regulatory Documentation: CMC writing, stability studies (ICH Q1A), method validation (ICH Q2(R1)), process validation (PPQ), impurity qualification (ICH Q3A, Q3B), and regulatory submissions (IND, IMPD, BLA, MAA, NDA).
Market Segmentation by Type
- Common Primer Synthesis (40–45% of revenue, largest segment): Unmodified DNA/RNA oligonucleotides (standard phosphodiester backbone). Used for PCR primers, sequencing primers, qPCR probes, hybridization probes, and molecular diagnostics. GMP-grade for in vitro diagnostic (IVD) kits and clinical research (non-therapeutic). Lower cost, simpler synthesis, fewer impurities.
- Modified Primer Synthesis (55–60% of revenue, fastest-growing at 8–9% CAGR): Therapeutic oligonucleotides (ASOs, siRNA, aptamers, CpG, guide RNA) with chemical modifications for nuclease resistance (phosphorothioate, 2′-O-methyl, 2′-fluoro, 2′-MOE, LNA), enhanced affinity, and improved pharmacokinetics. Modified synthesis requires additional steps (specialty amidites, sulfurization, deprotection), longer cycle times, and more complex purification. Higher cost ($500–5,000 per gram vs. $100–500 for common primers). Driven by oligonucleotide therapeutic approvals and clinical pipelines.
Market Segmentation by Application
- Biotech Company (65–70% of revenue, largest segment): Oligonucleotide therapeutics developers (Ionis, Alnylam, Sarepta, Biogen, Novartis, Moderna, CRISPR Therapeutics). Clinical-stage (Phase I/II/III) and commercial products. GMP-grade oligonucleotides for drug substance (API) and drug product (formulated). CDMO outsourcing due to lack of in-house GMP synthesis capacity, high capital investment ($10–50M for GMP suite), and regulatory expertise.
- Academic Scientific Research Institution (30–35% of revenue, fastest-growing at 8–9% CAGR): University labs, research institutes, non-profit organizations. GMP-grade oligonucleotides for IND-enabling studies (toxicology, pharmacology), investigator-initiated trials, and translational research. Smaller batches (1–10 mmol), higher cost per gram ($1,000–10,000/g vs. $500–1,000/g for biotech). Growing demand for GMP CRISPR guide RNA (gRNA) for ex vivo gene editing (CAR-T, TCR-T, iPSCs).
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Scale-up from research to GMP (1 µmol to 100+ mmol) requires validated synthesis columns (packed bed, radial flow), optimized coupling efficiency (>99% per cycle), and impurity control (truncated sequences increase exponentially with length). Length >50 nucleotides has lower yield (<50%) and higher impurity levels. Phosphorothioate (PS) stereochemistry for ASOs (e.g., Spinraza, Exondys 51) requires control of Rp/Sp diastereomers (affects nuclease resistance, protein binding, potency). Stereo-defined PS synthesis (chiral amidites) under development but not yet widely adopted for GMP. Purification scalability for long oligonucleotides (>50 nt) with high impurity levels (N-1, N-2, deletion) requires orthogonal purification methods (IEX + RP), increasing cost and reducing yield. Analytical characterization for modified oligonucleotides (multiple chiral centers, isobaric impurities, degradation products) requires advanced methods (LC-MS/MS, 2D-LC, ion mobility). Reference standards for each impurity challenging.
独家观察: siRNA and ASO Commercial Success Driving GMP Oligo Demand
An original observation from this analysis is the double-digit growth (8–9% CAGR) of GMP oligonucleotide production for siRNA (Alnylam: Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio) and ASO (Ionis/Biogen: Spinraza; Sarepta: Exondys 51, Vyondys 53, Viltepso). siRNA requires 21–23 nt double-stranded RNA with 2′-O-methyl and phosphorothioate modifications; ASOs require 16–20 nt single-stranded DNA with phosphorothioate backbone and 2′-MOE or LNA modifications. Commercial products require multi-kilogram quantities (100–1,000 kg/year), driving CDMO capacity expansion (Thermo Fisher, Merck, Azenta, TriLink). siRNA/ASO segment projected 60%+ of GMP oligo revenue by 2030 (vs. 45% in 2025). Additionally, CRISPR guide RNA (gRNA) for ex vivo gene editing (CAR-T, TCR-T, iPSC) is an emerging application (10–12% CAGR). GMP gRNA (100–200 nt, chemically modified) required for IND-enabling studies and clinical trials. High purity (>95%), long sequence length, and complex modifications challenge current GMP synthesis capacity.
Strategic Outlook for Industry Stakeholders
For CEOs, product line managers, and biopharma investors, the GMP oligonucleotide production market represents a high-growth (8.1% CAGR), high-margin CDMO opportunity anchored by oligonucleotide therapeutic approvals, siRNA/ASO commercial success, and CRISPR gene editing pipelines. Key strategies include:
- Investment in large-scale GMP synthesis capacity (100–500+ mmol, 100–1,000+ columns) for commercial siRNA and ASO products (multi-kilogram scale).
- Development of modified oligonucleotide synthesis expertise (2′-MOE, LNA, 2′-fluoro, phosphorothioate stereochemistry) for therapeutic oligos (ASO, siRNA, aptamers, CpG, gRNA).
- Expansion into CRISPR guide RNA (gRNA) GMP production (100–200 nt, high purity) for ex vivo gene editing (CAR-T, TCR-T, iPSC, HSC) and in vivo delivery (lipid nanoparticles, AAV).
- Geographic expansion into Asia-Pacific (China, South Korea, Japan) for oligonucleotide CDMO outsourcing and North America/Europe for commercial supply.
Companies that successfully combine large-scale synthesis, modified oligonucleotide chemistry, and regulatory expertise (FDA, EMA, PMDA, NMPA) will capture share in a $642 million market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
